Blog
Daily evidence-led peptide research, regulatory news, expert digest and explainers. Every claim sourced; no AI tells.
Page 15
CJC-1295 Side Effects in Human Trials
Early CJC-1295 trials reported no serious reactions, but lacked a full public event table and cannot establish long-term safety.
Is CJC-1295 Prohibited by WADA?
CJC-1295 is named in WADA section S2.2.4 and is prohibited in and out of competition under the 2026 Prohibited List.
GSD Ia and a Semaglutide Case Report
A 2026 case report shows why a rare glucose-storage disorder changed the semaglutide plan for one adolescent with obesity and liver lesions.
Ipamorelin cost in Germany: the facts
No official German ipamorelin pharmacy price could be verified. Here is what the EU, reimbursement and vendor-price records show.
Oral Semaglutide and CVR R
A small retrospective study linked lower deep breathing CVR R with early oral semaglutide discontinuation. It cannot predict an individual's tolerance.
How PT-141 works in the brain
PT-141 activates melanocortin receptors in the brain, but the full path from receptor binding to changes in sexual desire remains unknown.
Retatrutide history: 2022 to today
Retatrutide moved from a 2022 discovery paper to Phase 3 obesity results in four years, but it remains investigational and unapproved.
How retatrutide works: three receptors
Retatrutide activates GIP, GLP-1 and glucagon receptors, combining appetite and glucose signals with a proposed energy-expenditure effect.
Selank: Is There a Best Time of Day?
No human study establishes a best time of day for Selank or shows that morning, afternoon, or bedtime use changes sleep.
Beyond LDL-C: Three Complex Cases
A 2026 case-based review shows how ApoB, particle measures, imaging and genetics can add context when LDL-C tells only part of the story.
CJC-1295 No DAC and Visceral Fat
Human CJC-1295 studies did not test no-DAC material for visceral fat loss, so they cannot support a starting dose or cycle.
Diabetes Drugs After 65: 2026 Review
A 2026 review weighs tirzepatide and other diabetes drugs for older adults against frailty, hypoglycaemia and treatment burden.